Millennium Management
VYGR icon

Millennium Management’s Voyager Therapeutics VYGR Stock Holding History

Millennium Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,800
Closed -$176K – 6453
2025
Q4 		$176K Sell
44,800
-5,500
-11% -$24.3K ﹤0.01% 5502
2025
Q3 		$235K Buy
+50,300
New +$182K ﹤0.01% 5466
2022
Q2 		– Sell
-30,000
Closed -$229K – 7562
2022
Q1 		$229K Buy
+30,000
New +$134K ﹤0.01% 5753

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management's VYGR Position: Q1 2026 in Review

Millennium Management increased its Voyager Therapeutics (VYGR) stake by 82% in Q1 2026, buying an estimated $6.09M and bringing the position to 3,428,571 shares worth $13.2M. The position accounts for 0.01% of the portfolio, ranked #1908.

Millennium Management first reported a position in VYGR in Q4 2017 and has held it in 27 quarters since. The position peaked at $13.3M in Q2 2019. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Millennium Management held 3,428,571 shares of Voyager Therapeutics worth $13.2M as of Q1 2026.
  • Millennium Management bought 1,547,811 Voyager Therapeutics shares in Q1 2026, an estimated $6.09M.
  • Voyager Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1908 holding.
  • Millennium Management first reported a position in Voyager Therapeutics in Q4 2017 and has held it in 27 quarters since.
  • Millennium Management's Voyager Therapeutics position peaked at $13.3M in Q2 2019.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.